This is a special medicine used to treat a type of leukemia (cancer of the blood). It's a combination of an antibody and an antibiotic that targets cancer cells.
Every report comes from a Lived member, sent anonymously.
Have you tried Besponsa (Inotuzumab Ozogamicin) for B-Cell Acute Lymphoblastic Leukemia?
Inotuzumab ozogamicin, sold as Besponsa, is a targeted cancer medicine for B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a fast-growing blood cancer that starts in the bone marrow, and the B-cell precursor type arises from immature cells that would normally become B lymphocytes, a kind of white blood cell. Besponsa is approved for ALL that has come back after treatment (relapsed) or has not responded to it (refractory), in adults and in children 1 year and older. The leukemia cells must carry a surface protein called CD22, which lab testing confirms before treatment. A common goal is to bring the leukemia into remission so that a stem cell transplant becomes possible. In the US, Besponsa is not approved as a first treatment for newly diagnosed ALL.
Besponsa is an antibody-drug conjugate: a lab-made antibody chemically joined to a potent cell-killing drug. The antibody part, inotuzumab, recognizes CD22 on the surface of leukemia cells. Once it attaches, the cell pulls the antibody and its cargo inside. There the link breaks and releases calicheamicin, a toxin that snaps both strands of the cell's DNA, so the cell stops dividing and dies. This design aims the toxin at cells that carry CD22 instead of exposing every dividing cell equally, as standard chemotherapy does. The targeting is not perfect, however. The drug can still damage the liver and the bone marrow, and those effects drive its most important risks.
Besponsa is given only in a hospital or infusion center, as an infusion into a vein that takes about an hour. Before each dose, people receive a corticosteroid, a fever reducer and an antihistamine to lower the chance of an infusion reaction, and they are watched for at least an hour afterward. If many leukemia cells are circulating in the blood, other medicines are usually used first to bring that count down. Treatment runs in cycles of three to four weeks, with doses on days 1, 8 and 15. The dose is calculated from body size, and later cycles are adjusted depending on whether the leukemia is in remission. People heading to a stem cell transplant usually receive two cycles (occasionally three), because more cycles raise the risk of serious liver damage after transplant. People not going to transplant can receive up to six cycles. If the leukemia is not in remission after three cycles, Besponsa is stopped. The care team may delay doses, lower them or stop the drug based on blood counts and liver tests.
Low blood counts are the most common effect and the most common reason doses are delayed. Low platelets can cause easy bruising, nosebleeds or other bleeding, and low white cells make infections more likely. In the main adult trial, about half of patients had an infection, and some infections were life-threatening or fatal. Fever, tiredness, nausea, vomiting, headache and abdominal pain are also common, and blood tests often show raised liver enzymes or bilirubin. The most serious risk, and the subject of the drug's boxed warning (the FDA's most prominent safety warning), is liver damage, including veno-occlusive disease (VOD, also called sinusoidal obstruction syndrome). VOD can make the liver swell and fluid collect in the abdomen, and it can be fatal. In the adult trial it affected 14% of patients overall and 23% of those who later had a stem cell transplant. It can appear during treatment, weeks after the last dose or after a transplant. Contact the care team right away for rapid weight gain, a swollen or painful belly, or yellowing of the skin or eyes. Also call right away for fever, chills or other signs of infection, and for bleeding that is unusual or hard to stop. Infusion reactions are uncommon. Tell the nurse at once about chills, fever, rash or trouble breathing during or soon after an infusion.
A second boxed warning concerns stem cell transplant. In the adult trial, people who received Besponsa before a transplant were more likely to die after the transplant from causes other than the leukemia, mainly VOD and infections: 39% compared with 23% among those who had standard chemotherapy before transplant. The risk of VOD after transplant is higher when the conditioning treatment (the chemotherapy given just before a transplant) includes two alkylating drugs, a common class of chemotherapy, and when bilirubin is raised beforehand. Prior liver disease, a previous transplant, older age and more cycles of Besponsa also raise the risk. These are the reasons cycles are limited before transplant and liver tests are checked at least weekly during the first month after it. People who have had VOD before or have serious ongoing liver disease, such as cirrhosis or active hepatitis, face a higher risk and should weigh it carefully with their team. Besponsa can lengthen the QT interval, a measurement on an electrocardiogram (ECG) of how long the heart takes to reset between beats. A markedly long QT can trigger dangerous rhythm problems. The team checks an ECG and blood electrolytes before and during treatment, and avoids or closely monitors other medicines known to prolong QT. Report dizziness, lightheadedness or fainting, and tell the team about every medicine and supplement you take. Besponsa can harm a developing baby and may reduce fertility. A pregnancy test is done before starting. Women who could become pregnant should use effective birth control during treatment and for 8 months after the last dose, and men with partners who could become pregnant should do so for 5 months after. Breastfeeding should be avoided during treatment and for 2 months after the last dose.
Treatment means weekly visits for doses, blood counts and liver tests, plus close follow-up between cycles. In the main adult trial, about three in four people reached complete remission (no leukemia visible in the bone marrow, sometimes with blood counts still recovering), compared with about three in ten on standard intensive chemotherapy. A higher share also reached a deeper response in which sensitive tests could not detect remaining leukemia, called minimal residual disease (MRD) negativity. In a study of children, about four in ten reached complete remission, nearly all of them MRD negative. A survival advantage over chemotherapy was not statistically confirmed in the final analysis described on the label, so the clearest benefit is the higher chance of remission. For many people Besponsa is a bridge: about half of adults in the trial went on to a stem cell transplant, compared with about one in five on chemotherapy. Those who are not heading to transplant may continue for up to six cycles. Blood counts can stay low for weeks, and in some people platelets take longer than six weeks after the last dose to recover, so infection precautions, preventive anti-infective medicines and transfusions are often part of care. Liver monitoring continues after the last dose, especially after a transplant.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Besponsa (Inotuzumab Ozogamicin), what you've noticed, or ask the community a question.